201 related articles for article (PubMed ID: 9170469)
21. [Second trimester maternal serum screening for Down's syndrome in mainland China: a multi-center prospective study].
Bian XM; Liu JT; Qi QW; Jiang YL; Li Y; Liu SY; Hao N; Zhou J; Lü SM; Zhu BS; Wang H; Xu ZF; Pan XY; Liao C; Cai Y; Wang H; Wang Z; Zhu J; Hu YL
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):805-9. PubMed ID: 19087560
[TBL] [Abstract][Full Text] [Related]
22. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
23. Screening for Down's syndrome and neural tube defect in Croatia. A regional prospective study.
Brajenović-Milić B; Tislarić D; Bacić J; Paravić J; Slivar AE; Kapovic M; Kosec V; Ristic S; Rajhvajn B
Fetal Diagn Ther; 1998; 13(6):367-71. PubMed ID: 9933821
[TBL] [Abstract][Full Text] [Related]
24. [AFP, uE3, beta-hCG levels applied for prenatal diagnosis of Down's syndrome].
Liao S; Wang Y; Ye G
Zhonghua Fu Chan Ke Za Zhi; 1997 Nov; 32(11):655-8. PubMed ID: 9639764
[TBL] [Abstract][Full Text] [Related]
25. Ultrasound detection of placental insufficiency in women with elevated second trimester serum alpha-fetoprotein or human chorionic gonadotropin.
Toal M; Chaddha V; Windrim R; Kingdom J
J Obstet Gynaecol Can; 2008 Mar; 30(3):198-206. PubMed ID: 18364097
[TBL] [Abstract][Full Text] [Related]
26. A risk prediction model for fetal hypospadias by testing maternal serum AFP and free beta-HCG.
Chen Y; Huang J; Mei J
Clin Biochem; 2019 Jul; 69():21-25. PubMed ID: 31152694
[TBL] [Abstract][Full Text] [Related]
27. [Abnormal second trimester screening for fetal chromosomal abnormalities as a predictor of adverse pregnancy outcome].
Baś-Budecka E; Perenc M; Sieroszewski P
Ginekol Pol; 2007 Nov; 78(11):877-80. PubMed ID: 18306921
[TBL] [Abstract][Full Text] [Related]
28. Adverse perinatal outcome in patients screen-positive for neural tube defects and fetal Down syndrome.
Gross SJ; Phillips OP; Shulman LP; Bright NL; Dungan JS; Simpson JL; Elias S
Prenat Diagn; 1994 Jul; 14(7):609-13. PubMed ID: 7526367
[TBL] [Abstract][Full Text] [Related]
29. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: a seven year review.
Spencer K
Br J Obstet Gynaecol; 1999 Dec; 106(12):1287-93. PubMed ID: 10609723
[TBL] [Abstract][Full Text] [Related]
30. Maternal serum screening for Down syndrome in a teaching hospital in Hong Kong.
Law L; Lau T; Fung T; Rogers MS; Hjelm M
Chin Med J (Engl); 1999 Aug; 112(8):754-7. PubMed ID: 11601289
[TBL] [Abstract][Full Text] [Related]
31. Maternal first trimester serum levels of free-beta human chorionic gonadotrophin and male genital anomalies.
Schneuer FJ; Bower C; Holland AJ; Tasevski V; Jamieson SE; Barker A; Lee L; Majzoub JA; Nassar N
Hum Reprod; 2016 Aug; 31(8):1895-903. PubMed ID: 27496947
[TBL] [Abstract][Full Text] [Related]
32. Maternal serum screening for down syndrome in pregnancies conceived by intra-uterine insemination.
Hsu TY; Ou CY; Hsu JJ; Kung FT; Chang SY; Soong YK
Prenat Diagn; 1999 Nov; 19(11):1012-4. PubMed ID: 10589050
[TBL] [Abstract][Full Text] [Related]
33. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Spencer K; Souter V; Tul N; Snijders R; Nicolaides KH
Ultrasound Obstet Gynecol; 1999 Apr; 13(4):231-7. PubMed ID: 10341399
[TBL] [Abstract][Full Text] [Related]
34. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes.
Tancrède S; Bujold E; Giguère Y; Renald MH; Girouard J; Forest JC
J Obstet Gynaecol Can; 2015 Feb; 37(2):111-6. PubMed ID: 25767942
[TBL] [Abstract][Full Text] [Related]
35. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
[TBL] [Abstract][Full Text] [Related]
36. Free beta-hCG subunit versus intact hCG in Down syndrome screening.
Wenstrom KD; Owen J; Chu DC; Boots L
Obstet Gynecol; 1997 Sep; 90(3):370-4. PubMed ID: 9277646
[TBL] [Abstract][Full Text] [Related]
37. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
[TBL] [Abstract][Full Text] [Related]
38. Hyperglycosylated human chorionic gonadotropin (invasive trophoblast antigen) immunoassay: A new basis for gestational Down syndrome screening.
Cole LA; Shahabi S; Oz UA; Bahado-Singh RO; Mahoney MJ
Clin Chem; 1999 Dec; 45(12):2109-19. PubMed ID: 10585342
[TBL] [Abstract][Full Text] [Related]
39. Combined measurement of fetal nuchal translucency, maternal serum free beta-hCG, and pregnancy-associated plasma protein A for first-trimester Down's syndrome screening.
Tsai MS; Huang YY; Hwa KY; Cheng CC; Lee FK
J Formos Med Assoc; 2001 May; 100(5):319-25. PubMed ID: 11432311
[TBL] [Abstract][Full Text] [Related]
40. Detection of maternal serum hCG glycoform variants in the second trimester of pregnancies affected by Down syndrome using a lectin immunoassay.
Talbot JA; Spencer K; Abushoufa RA
Prenat Diagn; 2003 Jan; 23(1):1-5. PubMed ID: 12533803
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
